DAFNA Capital Management LLC activity
Every position Nathan Fischel opened, added to, trimmed or closed between 2026 Q1 and 2026 Q2.
New
17
Add
17
Reduce
26
Exit
11
71 shown
| Ticker | Action | Δ weight | Detail | Period |
|---|---|---|---|---|
| ASND | New | 0% to 2.5% | $13M | Q1→Q2 |
| KYMR | New | 0% to 0.59% | $3.1M | Q1→Q2 |
| ANL | New | 0% to 0.53% | $2.8M | Q1→Q2 |
| NGEN | New | 0% to 0.41% | $2.2M | Q1→Q2 |
| RNA | New | 0% to 0.33% | $1.7M | Q1→Q2 |
| DSGN | New | 0% to 0.28% | $1.5M | Q1→Q2 |
| Eupraxia Pharmaceutic… | New | 0% to 0.28% | $1.5M | Q1→Q2 |
| CRBP | New | 0% to 0.19% | $1M | Q1→Q2 |
| SEG | New | 0% to 0.13% | $704K | Q1→Q2 |
| ARTV | New | 0% to 0.12% | $651K | Q1→Q2 |
| EDIT | New | 0% to 0.11% | $552K | Q1→Q2 |
| Scynexis | New | 0% to 0.11% | $553K | Q1→Q2 |
| QTTB | New | 0% to 0.08% | $419K | Q1→Q2 |
| Nuvectis Pharma | New | 0% to 0.07% | $368K | Q1→Q2 |
| Tenaya Therapeutics | New | 0% to 0.04% | $222K | Q1→Q2 |
| Engene Therapeutics | New | 0% to 0.02% | $129K | Q1→Q2 |
| Kardigan | New | 0% to 0.02% | $119K | Q1→Q2 |
| DAWN | Exit | 4.8% to 0% | $21M | Q1→Q2 |
| Kalvista Pharmaceutic… | Exit | 1.2% to 0% | $5.4M | Q1→Q2 |
| ASND | Exit | 1.2% to 0% | $5.3M | Q1→Q2 |
| FULC | Exit | 0.36% to 0% | $1.6M | Q1→Q2 |
| Engene | Exit | 0.29% to 0% | $1.3M | Q1→Q2 |
| SCYX | Exit | 0.23% to 0% | $997K | Q1→Q2 |
| ORIC | Exit | 0.22% to 0% | $945K | Q1→Q2 |
| ZBIO | Exit | 0.19% to 0% | $831K | Q1→Q2 |
| NAMS | Exit | 0.15% to 0% | $640K | Q1→Q2 |
| KPTI | Exit | 0.06% to 0% | $255K | Q1→Q2 |
| NMRA | Exit | 0.03% to 0% | $137K | Q1→Q2 |
| DNLI | Add | 1.4% to 3.6% | +132.0% sh | Q1→Q2 |
| NKTR | Add | 2.7% to 4.2% | +92.7% sh | Q1→Q2 |
| PODD | Add | 0.52% to 1.8% | +469.2% sh | Q1→Q2 |
| EWTX | Add | 0.80% to 1.8% | +102.1% sh | Q1→Q2 |
| KIDS | Add | 0.35% to 0.69% | +97.7% sh | Q1→Q2 |
| NGNE | Add | 0.26% to 0.53% | +57.2% sh | Q1→Q2 |
| SNDX | Add | 1.2% to 1.4% | +54.2% sh | Q1→Q2 |
| ANNX | Add | 0.15% to 0.32% | +152.8% sh | Q1→Q2 |
| AQST | Add | 0.35% to 0.51% | +75.3% sh | Q1→Q2 |
| MAZE | Add | 0.24% to 0.37% | +85.7% sh | Q1→Q2 |
| CYBN | Add | 0.54% to 0.65% | +3.2% sh | Q1→Q2 |
| IDYA | Add | 3.6% to 3.5% | +4.3% sh | Q1→Q2 |
| CTMX | Add | 0.25% to 0.31% | +90.6% sh | Q1→Q2 |
| ADCT | Add | 0.06% to 0.02% | +6.9% sh | Q1→Q2 |
| ALLO | Add | 0.76% to 0.79% | +46.0% sh | Q1→Q2 |
| MLYS | Add | 0.24% to 0.23% | +15.6% sh | Q1→Q2 |
| SPRY | Add | 0.25% to 0.25% | +17.9% sh | Q1→Q2 |
| RVMD | Reduce | 12.9% to 20.1% | −3.1% sh | Q1→Q2 |
| XBI | Reduce | 9.3% to 5.9% | −38.3% sh | Q1→Q2 |
| CMPS | Reduce | 3.0% to 5.4% | −16.8% sh | Q1→Q2 |
| BHVN | Reduce | 1.6% to 0.39% | −83.7% sh | Q1→Q2 |
| MBX | Reduce | 1.2% to 0.12% | −93.3% sh | Q1→Q2 |
| LRMR | Reduce | 2.1% to 1.2% | −1.0% sh | Q1→Q2 |
| NDAQ | Reduce | 2.4% to 1.5% | −31.4% sh | Q1→Q2 |
| CYTK | Reduce | 3.3% to 2.8% | −20.9% sh | Q1→Q2 |
| RCUS | Reduce | 2.2% to 2.6% | −0.5% sh | Q1→Q2 |
| BCAX | Reduce | 1.9% to 1.6% | −32.4% sh | Q1→Q2 |
| Immatics | Reduce | 0.51% to 0.23% | −48.2% sh | Q1→Q2 |
| NBIX | Reduce | 2.1% to 1.9% | −18.2% sh | Q1→Q2 |
| IMVT | Reduce | 0.85% to 1.1% | −0.7% sh | Q1→Q2 |
| KURA | Reduce | 0.44% to 0.25% | −48.9% sh | Q1→Q2 |
| BCRX | Reduce | 0.93% to 0.76% | −7.0% sh | Q1→Q2 |
| VRCA | Reduce | 0.18% to 0.03% | −84.5% sh | Q1→Q2 |
| ALGN | Reduce | 0.58% to 0.45% | −6.7% sh | Q1→Q2 |
| IPSC | Reduce | 1.3% to 1.1% | −1.4% sh | Q1→Q2 |
| FATE | Reduce | 0.15% to 0.27% | −4.5% sh | Q1→Q2 |
| ALKS | Reduce | 1.1% to 1.0% | −27.4% sh | Q1→Q2 |
| PROF | Reduce | 0.39% to 0.33% | −1.0% sh | Q1→Q2 |
| Compugen | Reduce | 0.12% to 0.07% | −34.7% sh | Q1→Q2 |
| AXGN | Reduce | 1.9% to 1.8% | −16.4% sh | Q1→Q2 |
| IBIO | Reduce | 0.08% to 0.06% | −12.2% sh | Q1→Q2 |
| PRQR | Reduce | 0.58% to 0.54% | −2.4% sh | Q1→Q2 |
| RARE | Reduce | 0.29% to 0.30% | −22.9% sh | Q1→Q2 |